Involvement of the inhibition of intestinal glucuronidation in enhancing the oral bioavailability of resveratrol by Labrasol containing nanoemulsions

Molecular Pharmaceutics

Volumn 12, Issue 4, 2015, Pages 1084-1095

  Zhou, Jing ^a   Zhou, Man ^a   Yang, Fei Fei ^a   Liu, Chun Yu ^a   Pan, Rui Le ^a   Chang, Qi ^a   Liu, Xin Min ^a   Liao, Yong Hong ^a  

^a INSTITUTE OF MEDICINAL PLANT DEVELOPMENT   (China)

Author keywords

glucuronidation; nanoemulsion; oral bioavailability; resveratrol; UDP glucuronosyltransferases (UGT)

Indexed keywords

LABRASOL; RESVERATROL; ACYLGLYCEROL; EMULSION; GLUCURONOSYLTRANSFERASE; NANOPARTICLE; PHENOL; STILBENE DERIVATIVE; URIDINE DIPHOSPHATE;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CACO 2 CELL LINE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG RELEASE; DRUG STABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MESENTERY LYMPH NODE; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG EFFECTS; EMULSION; INTESTINE; METABOLISM; MICROSOME; ORAL DRUG ADMINISTRATION; SMALL INTESTINE; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; EMULSIONS; GLUCURONOSYLTRANSFERASE; GLYCERIDES; HUMANS; INTESTINE, SMALL; INTESTINES; MALE; MICROSOMES; MICROSOMES, LIVER; NANOPARTICLES; PARTICLE SIZE; PHENOL; RATS; RATS, WISTAR; STILBENES; URIDINE DIPHOSPHATE;

EID: 84926442368     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp5005838     Document Type: Article

References (53)

1. Cavallaro, A.; Ainis, T.; Bottari, C.; Fimiani, V. Effect of resveratrol on some activities of isolated and in whole blood human neutrophils Physiol. Res. 2003, 52, 555-562
2. Pervaiz, S.; Holme, A. L. Resveratrol: its biologic targets and functional activity Antioxid. Redox Signaling 2009, 11, 2851-2897
3. Athar, M.; Back, J. H.; Tang, X.; Kim, K. H.; Kopelovich, L.; Bickers, D. R.; Kim, A. L. Resveratrol: a review of preclinical studies for human cancer prevention Toxicol. Appl. Pharmacol. 2007, 3, 274-283
4. Das, D. K.; Maulik, N. Resveratrol in cardioprotection: a therapeutic promise of alternative medicine Mol. Interventions 2006, 1, 36-47
5. Lagouge, M.; Argmann, C.; Gerhart-Hines, Z.; Meziane, H.; Lerin, C.; Daussin, F.; Messadeq, N.; Milne, J.; Lambert, P.; Elliott, P.; Geny, B.; Laakso, M.; Puigserver, P.; Auwerx, J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha Cell 2006, 6, 1109-1122
6. Szkudelski, T.; Szkudelska, K. Anti-diabetic effects of resveratrol Ann. N.Y. Acad. Sci. 2011, 1215, 34-39
7. Anekonda, T. S. Resveratrol-a boon for treating Alzheimers disease? Brain Res. Rev. 2006, 2, 316-326
8. Gertz, M.; Nguyen, G. T. T.; Fischer, F.; Suenkel, B.; Schlicker, C.; Fränzel, B.; Tomaschewski, J.; Aladini, F.; Becker, C.; Wolters, D.; Steegborn, C. A molecular mechanism for direct Sirtuin activation by resveratrol PLoS One 2012, 7, e49761
9. Santos, A. C.; Veiga, F.; Ribeiro, A. J. New delivery systems to improve the bioavailability of resveratrol. Expert Opin. Drug Delivery 2011, 8, 973-990
10. Amri, A.; Chaumeil, J. C.; Sfar, S. Administration of resveratrol: What formulation solutions to bioavailability limitations? J. Controlled Release 2012, 158, 182-193
11. Sessa, M.; Balestrieri, M. L.; Ferrari, G.; Servillo, L.; Castaldo, D.; DOnofrio, N.; Donsì, F.; Tsao, R. Bioavailability of encapsulated resveratrol into nanoemulsion-based delivery systems Food Chem. 2014, 147, 42-50
12. Amri, A.; Le-Clanche, S.; Thérond, P.; Bonnefont-Rousselot, D.; Borderie, D.; Lai-Kuen, R.; Chaumeil, J. C.; Sfar, S.; Charrueau, C. Resveratrol self-emulsifying system increases the uptake by endothelial cells and improves protection against oxidative stress-mediated death Eur. J. Pharm. Biopharm. 2014, 86, 418-426
13. Singh, G.; Pai, R. S. Trans-resveratrol self-nano-emulsifying drug delivery system (SNEDDS) with enhanced bioavailability potential: optimization, pharmacokinetics and in situ single pass intestinal perfusion (SPIP) studies Drug Delivery 2014, 1, 1-9
14. Baur, J. A.; Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence Nat. Rev. Drug Discovery 2006, 5, 493-506
15. Yu, C.; Shin, Y. G.; Chow, A.; Li, Y.; Kosmeder, J. W.; Lee, Y. S.; Hirschelman, W. H.; Pezzuto, J. M.; Mehta, R. G.; van Breemen, R. B. Human, rat, and mouse metabolism of resveratrol Pharm. Res. 2002, 19, 1907-1914
16. Wang, L. X.; Heredia, A.; Song, H.; Zhang, Z.; Yu, B.; Davis, C.; Redfield, R. Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti-HIV activity J. Pharm. Sci. 2004, 93, 2448-2457
17. Vitaglione, P.; Sforza, S.; Galaverna, G.; Ghidini, C.; Caporaso, N.; Vescovi, P. P.; Fogliano, V.; Marchelli, R. Bioavailability of trans-resveratrol from red wine in humans Mol. Nutr. Food Res. 2005, 49, 495-504
18. Sabolovic, N.; Humbert, A. C.; Radominska-Pandya, A.; Magdalou, J. Resveratrol is efficiently glucuronidated by UDP-glucuronosyltransferases in the human gastrointestinal tract and in Caco-2 cells Biopharm. Drug Dispos. 2006, 27, 181-189
19. de Santi, C.; Pietrabissa, A.; Mosca, F.; Pacifici, G. M. Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver Xenobiotica 2000, 30, 1047-1054
20. Brill, S. S.; Furimsky, A. M.; Ho, M. N.; Furniss, M. J.; Li, Y.; Green, A. G.; Bradford, W. W.; Green, C. E.; Kapetanovic, I. M.; Iyer, L. V. Glucuronidation of trans-resveratrol by human liver and intestinal microsomes and UGT isoforms J. Pharm. Pharmacol. 2006, 58, 469-479
21. Johnson, J. J.; Nihal, M.; Siddiqui, I. A.; Scarlett, C. O.; Bailey, H. H.; Mukhtar, H.; Ahmad, N. Enhancing the bioavailability of resveratrol by combining it with piperine Mol. Nutr. Food Res. 2011, 55, 1169-1176
22. Huang, W.; Chen, Z.; Wang, Q.; Lin, M.; Wu, S.; Yan, Q.; Wu, F.; Yu, X.; Xie, X.; Li, G.; Xu, Y.; Pan, J. Piperine potentiates the antidepressant-like effect of trans-resveratrol: involvement of monoaminergic system Metab. Brain Dis. 2013, 28, 585-595
23. Kim, A. R.; Lim, S. J.; Lee, B. J. Metabolic inhibition and kinetics of raloxifene by pharmaceutical excipients in human liver microsomes Int. J. Pharm. 2009, 368, 37-44
24. Argikar, U. A.; Liang, G.; Bushee, J. L.; Hosagrahara, V. P.; Lee, W. Evaluation of pharmaceutical excipients as cosolvents in 4-methyl umbelliferone glucuronidation in human liver microsomes: applications for compounds with low solubility Drug Metab. Pharmacokinet. 2011, 26, 102-106
25. Li, F.; Yang, X. W. Biotransformation of myrislignan by rat liver microsomes in vitro Phytochemistry 2008, 69, 765-771
26. Ghai, D.; Sinha, V. R. Nanoemulsions as self-emulsified drug delivery carriers for enhanced permeability of the poorly water-soluble selective β1-adrenoreceptor blocker Talinolol Nanomedicine 2012, 8, 618-626
27. Juan, M. E.; Maijó, M.; Planas, J. M. Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC J. Pharm. Biomed. Anal. 2010, 51, 391-398
28. Andlauer, W.; Kolb, J.; Siebert, K.; Fürst, P. Assessment of resveratrol bioavailability in the perfused small intestine of the rat Drugs Exp. Clin. Res. 2000, 26, 47-55
29. Planas, J. M.; Alfaras, I.; Colom, H.; Juan, M. E. The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters Arch. Biochem. Biophys. 2012, 527, 67-73
30. Yáñez, J. A.; Wang, S. W.; Knemeyer, I. W.; Wirth, M. A.; Alton, K. B. Intestinal lymphatic transport for drug delivery Adv. Drug Delivery Rev. 2011, 63, 923-942
31. Nauli, A. M.; Nauli, S. M. Intestinal transport as a potential determinant of drug bioavailability Curr. Clin. Pharmacol. 2013, 8, 247-255
32. Marier, J. F.; Vachon, P.; Gritsas, A.; Zhang, J.; Moreau, J. P.; Ducharme, M. P. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model J. Pharmacol. Exp. Ther. 2002, 302, 369-373
33. Lawrence, M. J.; Rees, G. D. Microemulsion-based media as novel drug delivery systems Adv. Drug Delivery Rev. 2000, 6, 89-121
34. Kohli, K.; Chopra, S.; Dhar, D.; Arora, S.; Khar, R. K. Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability Drug Discovery Today 2010, 15, 958-965
35. Seljak, K. B.; Berginc, K.; Trontelj, J.; Zvonar, A.; Kristl, A.; Gašperlin, M. A self-microemulsifying drug delivery system to overcome intestinal resveratrol toxicity and presystemic metabolism J. Pharm. Sci. 2014, 103, 3491-500
36. Aumont, V.; Krisa, S.; Battaglia, E.; Netter, P.; Richard, T.; Mérillon, J. M.; Magdalou, J.; Sabolovic, N. Regioselective and stereospecific glucuronidation of trans- and cis-resveratrol in human Arch. Biochem. Biophys. 2001, 393, 281-289
37. Sharan, S.; Iwuchukwu, O. F.; Canney, D. J.; Zimmerman, C. L.; Nagar, S. In vivo-formed versus preformed metabolite kinetics of trans-resveratrol-3-sulfate and trans-resveratrol-3-glucuronide Drug Metab. Dispos. 2012, 40, 1993-2001
38. Gao, K.; Sun, J.; Liu, K.; Liu, X.; He, Z. Preparation and characterization of a submicron lipid emulsion of docetaxel: submicron lipid emulsion of docetaxel Drug Dev. Ind. Pharm. 2008, 34, 1227-1237
39. Yalin, M.; Oner, F.; Oner, L.; Hincal, A. A. Preparation and properties of a stable intravenous lorazepam emulsion J. Clin. Pharm. Ther. 1997, 22, 39-44
40. Porter, C. J. H.; Trevaskis, N. L.; Charman, W. N. Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs Nat. Rev. Drug Discovery 2007, 6, 231-248
41. Cabral, H.; Matsumoto, Y.; Mizuno, K.; Chen, Q.; Murakami, M.; Kimura, M.; Terada, Y.; Kano, M. R.; Miyazono, K.; Uesaka, M.; Nishiyama, N.; Kataoka, K. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size Nat. Nanotechnol. 2011, 23, 815-823
42. Ren, X.; Mao, X.; Cao, L.; Xue, K.; Si, L.; Qiu, J.; Schimmer, A. D.; Li, G. Nonionic surfactants are strong inhibitors of cytochrome P450 3A biotransformation activity in vitro and in vivo Eur. J. Pharm. Sci. 2009, 2, 401-411
43. Zhao, G.; Huang, J.; Xue, K.; Si, L.; Li, G. Enhanced intestinal absorption of etoposide by self-microemulsifying drug delivery systems: roles of P-glycoprotein and cytochrome P450 3A inhibition Eur. J. Pharm. Sci. 2013, 50, 429-439
44. Das, S.; Lin, H. S.; Ho, P. C.; Ng, K. Y. The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol Pharm. Res. 2008, 25, 2593-2600
45. Trela, B. C.; Waterhouse, A. L. Resveratrol: isomeric molar absorptivities and stability J. Agric. Food Chem. 1996, 44, 1253-1257
46. Gao, F.; Zhang, Z.; Bu, H.; Huang, Y.; Gao, Z.; Shen, J.; Zhao, C.; Li, Y. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: Performance and mechanism J. Controlled Release 2011, 149, 168-174
47. Singh, B.; Singh, R.; Bandyopadhyay, S.; Kapil, R.; Garg, B. Optimized nanoemulsifying systems with enhanced bioavailability of carvedilol Colloids Surf., B 2013, 1, 465-474
48. Luhmann, T.; Rimann, M.; Bittermann, A. G.; Hall, H. Cellular uptake and intracellular pathways of PLL-g-PEG-DNA nanoparticles Bioconjugate Chem. 2008, 19, 1907-1916
49. Hu, L.; Jia, Y.; Niu, F.; Jia, Z.; Yang, X.; Jiao, K. Preparation and enhancement of oral bioavailability of curcumin using microemulsions vehicle J. Agric. Food Chem. 2012, 60, 7137-7141
50. Xiao, Y.; Chen, X.; Yang, L.; Zhu, X.; Zou, L.; Meng, F.; Ping, Q. Preparation and oral bioavailability study of curcuminoid-loaded microemulsion J. Agric. Food Chem. 2013, 61, 3654-3660
51. Tran, T. H.; Guo, Y.; Song, D.; Bruno, R. S.; Lu, X. Quercetin-containing self-nanoemulsifying drug delivery system for improving oral bioavailability J. Pharm. Sci. 2014, 103, 840-852
52. Parveen, R.; Baboota, S.; Ali, J.; Ahuja, A.; Vasudev, S. S.; Ahmad, S. Oil based nanocarrier for improved oral delivery of silymarin: In vitro and in vivo studies Int. J. Pharm. 2011, 413, 245-253
53. Elsheikh, M. A.; Elnaggar, Y. S.; Gohar, E. Y.; Abdallah, O. Y. Nanoemulsion liquid preconcentrates for raloxifene hydrochloride: optimization and in vivo appraisal Int. J. Nanomed. 2012, 7, 3787-3802